Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10522317rdf:typepubmed:Citationlld:pubmed
pubmed-article:10522317lifeskim:mentionsumls-concept:C0004364lld:lifeskim
pubmed-article:10522317lifeskim:mentionsumls-concept:C0085297lld:lifeskim
pubmed-article:10522317lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:10522317pubmed:dateCreated1999-10-28lld:pubmed
pubmed-article:10522317pubmed:abstractTextIntravenous immunoglobulins (IVIg) therapy has been reported to be beneficial in a large number of autoantibody-mediated or self-reactive T cells-associated autoimmune diseases. Thus, the beneficial effect of IVIg is probably due to multiple distinct mechanisms.lld:pubmed
pubmed-article:10522317pubmed:languagefrelld:pubmed
pubmed-article:10522317pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10522317pubmed:citationSubsetIMlld:pubmed
pubmed-article:10522317pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10522317pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10522317pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10522317pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10522317pubmed:statusMEDLINElld:pubmed
pubmed-article:10522317pubmed:issn0248-8663lld:pubmed
pubmed-article:10522317pubmed:authorpubmed-author:KazatchkineM...lld:pubmed
pubmed-article:10522317pubmed:authorpubmed-author:KaveriS VSVlld:pubmed
pubmed-article:10522317pubmed:authorpubmed-author:MouthonLLlld:pubmed
pubmed-article:10522317pubmed:authorpubmed-author:Lacroix-Desma...lld:pubmed
pubmed-article:10522317pubmed:authorpubmed-author:PashovAAlld:pubmed
pubmed-article:10522317pubmed:issnTypePrintlld:pubmed
pubmed-article:10522317pubmed:volume20 Suppl 4lld:pubmed
pubmed-article:10522317pubmed:ownerNLMlld:pubmed
pubmed-article:10522317pubmed:authorsCompleteYlld:pubmed
pubmed-article:10522317pubmed:pagination423s-430slld:pubmed
pubmed-article:10522317pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10522317pubmed:meshHeadingpubmed-meshheading:10522317...lld:pubmed
pubmed-article:10522317pubmed:meshHeadingpubmed-meshheading:10522317...lld:pubmed
pubmed-article:10522317pubmed:meshHeadingpubmed-meshheading:10522317...lld:pubmed
pubmed-article:10522317pubmed:meshHeadingpubmed-meshheading:10522317...lld:pubmed
pubmed-article:10522317pubmed:meshHeadingpubmed-meshheading:10522317...lld:pubmed
pubmed-article:10522317pubmed:meshHeadingpubmed-meshheading:10522317...lld:pubmed
pubmed-article:10522317pubmed:meshHeadingpubmed-meshheading:10522317...lld:pubmed
pubmed-article:10522317pubmed:meshHeadingpubmed-meshheading:10522317...lld:pubmed
pubmed-article:10522317pubmed:meshHeadingpubmed-meshheading:10522317...lld:pubmed
pubmed-article:10522317pubmed:meshHeadingpubmed-meshheading:10522317...lld:pubmed
pubmed-article:10522317pubmed:year1999lld:pubmed
pubmed-article:10522317pubmed:articleTitle[Immunomodulatory effects of intravenous immunoglobulins in autoimmune diseases].lld:pubmed
pubmed-article:10522317pubmed:affiliationInserm U430, Hôpital Broussais, Paris.lld:pubmed
pubmed-article:10522317pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10522317pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:10522317pubmed:publicationTypeReviewlld:pubmed